Trials / Completed
CompletedNCT02796105
Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors
Evaluation of Efficacy and Safety of Medroxiprogesterone Acetate (Progevera 10 mg®) Versus GnRh Antagonist (Orgalutran®) in Ovarian Stimulation Cycles of Oocyte Donors
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 232 (actual)
- Sponsor
- Fundació Privada Eugin · Academic / Other
- Sex
- Female
- Age
- 18 Years – 35 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of efficacy and safety of medroxiprogesterone acetate (Progevera 10 mg®) versus GnRh antagonist (Orgalutran®) in ovarian stimulation cycles of oocyte donors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Progevera | |
| DRUG | Orgalutran |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2017-07-01
- Completion
- 2017-07-10
- First posted
- 2016-06-10
- Last updated
- 2017-09-13
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT02796105. Inclusion in this directory is not an endorsement.